<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of metastatic and recurrent head and neck cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of metastatic and recurrent head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of metastatic and recurrent head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Everett E Vokes, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is 6 to 15 months depending on patient- and disease-related factors. Symptom-directed care plays an important role in the management of these patients. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Head and neck cancer'</a> and  <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care"</a>.)</p><p>Systemic therapy is indicated for most patients with metastatic or advanced recurrent squamous cell carcinoma of the head and neck. The choice of systemic regimen is influenced by multiple clinical factors, including patient comorbidities, performance status, previous therapy, and pathologic features (ie, programmed death ligand 1 [PD-L1] expression status). Systemic treatment options include the following, administered as single-agent therapy or in combination:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors (ICIs)</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional cytotoxic chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Molecularly targeted agents (eg, epidermal growth factor receptor [EGFR] inhibitors)</p><p></p><p>The approach to systemic therapy for metastatic or advanced recurrent squamous cell carcinoma of the head and neck is reviewed here, along with the management of oligometastatic disease. The use of chemotherapy as a component of initial definitive therapy is discussed separately, as is the use of systemic chemotherapy in other malignancies of the head and neck region:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3381.html" rel="external">"Treatment of recurrent and metastatic nasopharyngeal carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3367.html" rel="external">"Head and neck sarcomas"</a>.)</p><p></p><p class="headingAnchor" id="H613874943"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>The general initial treatment approach to a patient with recurrent or metastatic squamous cell carcinoma of the head and neck is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>).</p><p>The treatment approach is influenced by prior therapies (surgery, radiation, chemotherapy), patient performance status and comorbidities, and tumor programmed death ligand 1 (PD-L1) expression status.</p><p>When assessing the trials described in this topic, it is important to remember that contemporary studies may be complicated by lead time bias that results from more sensitive diagnostic techniques, leading to earlier detection of asymptomatic metastases in patients receiving radiologic monitoring, and the inclusion of more patients with more favorable prognosis (ie, human papillomavirus [HPV] related metastatic tumors).</p><p class="headingAnchor" id="H613874950"><span class="h2">Clinical settings</span><span class="headingEndMark"> — </span>Systemic therapy is chosen based on exposure to previous therapies and the distribution of disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Oligometastatic disease (see <a class="local">'Oligometastatic disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Locally recurrent disease (see <a class="local">'Locally recurrent disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No prior systemic therapy (see <a class="local">'Previously untreated patients'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous systemic therapy for initial diagnosis of locoregional disease (see <a class="local">'Previous systemic therapy for locoregional disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous systemic therapy after diagnosis of recurrent or metastatic disease (see <a class="local">'Subsequent therapy'</a> below)</p><p></p><p class="headingAnchor" id="H2975856166"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>Patient-specific factors that influence prognosis need to be considered when choosing therapy. Factors associated with longer survival in patients include the following [<a href="#rid1">1-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ambulatory performance status (Eastern Cooperative Oncology Group [ECOG] 0 or 1 versus 2  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>))</p><p class="bulletIndent1"><span class="glyph">●</span>Prior response to chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Longer time since completion of definitive therapy</p><p class="bulletIndent1"><span class="glyph">●</span>HPV associated oropharyngeal cancers</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor PD-L1 expression status based on combined positive score (CPS), a predictive marker for response to anti-programmed cell death protein 1 (PD-1)</p><p></p><p>In contrast, factors associated with a poor prognosis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss</p><p class="bulletIndent1"><span class="glyph">●</span>Poor performance status</p><p class="bulletIndent1"><span class="glyph">●</span>Prior radiation therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Active smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Significant comorbidity</p><p></p><p>Increasing age is often associated with increasing comorbidity. However, evidence suggests that healthy older adult patients with metastatic and recurrent head and neck cancer have survival outcomes comparable to younger patients, but they may experience increased toxicity [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H613875239"><span class="h1">ACTIVE AGENTS</span><span class="headingEndMark"> — </span>Conventional cytotoxic drugs, immune checkpoint inhibitors (ICIs), and molecularly targeted compounds all have activity in metastatic and recurrent head and neck cancer. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>ICIs </strong>– <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">Pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) is a checkpoint inhibitor of programmed cell death protein 1 (PD-1). It has shown activity, alone or with chemotherapy, in previously untreated patients with advanced squamous cell carcinoma of the head and neck. Both pembrolizumab and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>), another PD-1 checkpoint inhibitor, have also shown clinically significant activity in patients who progressed on or after platinum-based regimens [<a href="#rid8">8-11</a>]. </p><p></p><p class="bulletIndent1">Further information regarding the use of immunotherapy for advanced squamous cell carcinoma of the head and neck in the first-line and second-line settings is discussed below. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> below and <a class="local">'PD-1 inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platinum-based chemotherapy</strong> – The platinum agents <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> are used both as single agents and to form the backbone for most combination regimens [<a href="#rid12">12-19</a>].</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is often considered to be less systemically effective than <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in head and neck cancer, there is little direct evidence. Carboplatin may be preferred in some cases since it is associated with less neurotoxicity, nephrotoxicity, ototoxicity, and nausea and vomiting compared with cisplatin, although carboplatin causes more myelosuppression [<a href="#rid20">20-23</a>]. In addition, carboplatin has much shorter infusion times than cisplatin. Adequately powered randomized trials directly comparing cisplatin with carboplatin as single agents and in multidrug regimens are lacking in this patient population.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Of the three studies that have compared the combination of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> for induction chemotherapy in patients with locally advanced disease [<a href="#rid20">20,21,24</a>], only one showed a statistically increased response rate and survival with the use of a cisplatin-based rather than carboplatin-based regimen [<a href="#rid21">21</a>]. Quality of life and treatment-related toxicity are considerations for patients who do not have a curative option.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, indirect evidence from the phase 3 trial assessing the role of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> in combination with a platinum-based regimen supports the use of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid25">25</a>]. In that trial, there was a similar improvement in progression-free survival (PFS) attributable to cetuximab in patients treated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and those given carboplatin plus fluorouracil, and there was no apparent difference in results between patients treated with the two platinum regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A Southwest Oncology Group (SWOG) trial showed similar survival for a regimen of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> versus <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus fluorouracil in the metastatic recurrent setting, with a nonstatistically significant improvement in response rate (32 versus 21 percent) and overall survival (OS; 7 versus 5 months) for the cisplatin-containing regimen [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other chemotherapy and targeted agents</strong> – In addition to platinum, taxanes (eg, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>) are the most active single-agent chemotherapy regimen. Other active agents include nanoparticle albumin-bound paclitaxel (<a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) [<a href="#rid26">26-30</a>], <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [<a href="#rid2">2</a>], and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid1">1,15,26</a>]. Other agents that may possess activity but have been less extensively evaluated include <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> [<a href="#rid31">31</a>], <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> [<a href="#rid32">32-36</a>], <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid37">37,38</a>], <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> [<a href="#rid39">39</a>], <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid40">40-43</a>], and <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid3">3,16,44</a>]. (See <a class="local">'Combination chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>), a targeted monoclonal antibody to epidermal growth factor receptor (EGFR), has activity alone or in combination with chemotherapy [<a href="#rid45">45</a>]. (See <a class="local">'Cetuximab with platinum-based chemotherapy'</a> below and <a class="local">'Cetuximab'</a> below.)</p><p></p><p class="headingAnchor" id="H3311337267"><span class="h1">OLIGOMETASTATIC DISEASE</span><span class="headingEndMark"> — </span>Patients with head and neck cancer with one or a limited number of distant metastases at presentation or relapse may benefit from aggressive treatment that includes eradication of all known sites of disease.</p><p>The most extensive data come from small series of patients with oligometastatic disease in the lungs, in whom disease in the primary site and regional lymph nodes has been completely controlled [<a href="#rid46">46</a>]. In this setting, surgical metastasectomy can result in prolonged disease-free survival in a significant percentage of appropriately selected patients. Data on oligometastatic disease involving sites other than the lung are more limited. (See  <a class="medical medical_review" href="/z/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers", section on 'Distinguishing second primary lung malignancies from distant metastasis'</a> and  <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a series that included 97 patients with squamous cell carcinoma from primary sites other than the oral cavity, the five-year overall survival (OS) rate was 32 percent [<a href="#rid47">47</a>]. Similarly, in a series of 83 patients from one institution, the five-year survival was 34 percent for the 41 patients with squamous cell carcinoma [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The primary site is an important factor influencing outcome. Patients with oligometastatic disease from a primary tumor of the oral cavity appear to have a significantly worse prognosis. As an example, in one series of 23 patients with a primary lesion of the oral tongue, 22 (96 percent) relapsed, with a median time to death of 10 months [<a href="#rid49">49</a>]. Similar poor results were seen in another series of 17 patients with oral cavity primary tumors, in which there were no five-year survivors [<a href="#rid47">47</a>].</p><p></p><p>Interpretation of these series is complicated by the possibility that some of these patients were surgically cured of one or more second primary squamous cell lung cancers rather than of a head and neck metastasis.</p><p>Other approaches to disease eradication, such as stereotactic body radiation therapy (SBRT), have also been used to treat one or a limited number of pulmonary metastases [<a href="#rid50">50</a>]. However, long-term follow-up data for SBRT are more limited compared with surgical resection. In one small randomized trial in patients with multiple metastatic sites, administering SBRT to a single metastatic site in combination with immunotherapy (<a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>)) did not improve response rates in "off-target" lesions or survival, compared with nivolumab alone [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Stereotactic radiation therapy techniques'</a> and  <a class="medical medical_review" href="/z/d/html/4617.html" rel="external">"Stereotactic body radiation therapy for lung tumors", section on 'Lung metastases'</a>.)</p><p>No clinical trials have been conducted to assess the role of adjuvant chemotherapy following surgical resection of all metastatic disease sites. Although there may be benefit to adjuvant chemotherapy, there is no evidence to make a recommendation for its use in this situation.</p><p class="headingAnchor" id="H3689464420"><span class="h1">LOCALLY RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Patients with locally recurrent head and neck cancer present a therapeutic challenge. Treatment options are limited, and morbidity can be substantial. Nevertheless, selected patients with recurrent disease may achieve long-term survival. The treatment of locally recurrent disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3373.html" rel="external">"Treatment of locally recurrent squamous cell carcinoma of the head and neck"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PREVIOUSLY UNTREATED PATIENTS</span></p><p class="headingAnchor" id="H2542925107"><span class="h2">Selection of therapy</span><span class="headingEndMark"> — </span>The choice of therapy for patients with advanced head and neck cancer who have not received prior systemic therapy is affected by the patient's performance status, symptoms related to locoregional disease burden, comorbidities, and programmed death ligand 1 (PD-L1) combined positive score (CPS) from biopsy specimens  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). This includes patients who initially present with advanced disease and are not candidates for definitive therapy, as well as those who develop metastatic or incurable locally recurrent disease following local treatment (surgery and/or radiation therapy [RT]) without chemotherapy.</p><p>The KEYNOTE-048 trial established the use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, with or without chemotherapy, as a first-line regimen for eligible patients with metastatic or recurrent squamous cell carcinoma of the head and neck [<a href="#rid52">52-54</a>]. The addition of pembrolizumab to a platinum and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> combination  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) improves overall survival (OS) compared with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus a platinum and fluorouracil combination. For those with high PD-L1 expression (CPS ≥1), single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) also improves OS compared with cetuximab plus a platinum and fluorouracil combination, although a subgroup analysis suggests this is mainly driven by those with a CPS ≥20 [<a href="#rid53">53</a>]. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> below.)</p><p>For patients with no prior systemic chemotherapy or immunotherapy and who are eligible for combination therapy based on performance status and comorbidities, we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with rapidly progressive disease may benefit from a more rapid tumor response. For such patients who are eligible for combination chemotherapy plus immunotherapy, we suggest the use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with a platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>), regardless of CPS. Alternatively, some contributors substitute a taxane (<a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) for the fluorouracil. (See <a class="local">'Pembrolizumab with platinum plus taxane'</a> below.)</p><p></p><p class="bulletIndent1">However, for patients who are not eligible for combination therapy, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) is an appropriate alternative. Some patients may also benefit from local therapy for symptom control prior to initiating systemic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those without rapidly progressive disease, our preferred approach is based on CPS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥20</strong> – We suggest single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) rather than pembrolizumab plus chemotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥1 and &lt;20</strong> – For patients with good performance status (eg, Eastern Cooperative Oncology Group [ECOG] performance status ≤2  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>)), we suggest <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with platinum-based chemotherapy rather than single-agent pembrolizumab. While chemotherapy regimens containing platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) are preferred, some contributors alternatively substitute a taxane (<a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) for the fluorouracil.</p><p></p><p class="bulletIndent2">For patients with a lesser performance status where it is preferred to avoid the potential toxicities of systemic chemotherapy, single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is a reasonable alternative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS &lt;1 or unavailable</strong> – We suggest platinum-based chemotherapy, with or without <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than other chemotherapy regimens.</p><p></p><p>For patients who are eligible for combination therapy but have a contraindication to immunotherapy, options include a doublet cytotoxic chemotherapy regimen, with or without concurrent or sequential <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). Doublet cytotoxic chemotherapy regimens, generally a platinum-based regimen with either a taxane or <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, increase the objective response rate (ORR) compared with single-agent chemotherapy, although no improvement in OS has been demonstrated. The addition of cetuximab to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus fluorouracil increases OS compared with cisplatin plus fluorouracil alone. (See <a class="local">'Combination chemotherapy'</a> below and <a class="local">'Cetuximab with platinum-based chemotherapy'</a> below.)</p><p>Patients not eligible for combination chemotherapy plus immunotherapy may be candidates for single-agent therapy. Options include a platinum (typically <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>), taxanes (eg, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>), <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). (See <a class="local">'Active agents'</a> above.)</p><p>Patients with severe comorbidities or a poor performance status may be best treated with supportive care. (See <a class="local">'Subsequent therapy'</a> below.)</p><p class="headingAnchor" id="H3016942213"><span class="h2">Pembrolizumab with or without platinum and fluorouracil</span><span class="headingEndMark"> — </span>For those with metastatic or recurrent head and neck cancer without prior exposure to systemic therapy, the combination of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus platinum-based chemotherapy  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) improves OS beyond that seen with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus chemotherapy [<a href="#rid52">52-55</a>]. For those with high PD-L1 expression, single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) also improves OS, compared with cetuximab plus chemotherapy, with less toxicity. Responses to pembrolizumab, either alone or in combination with chemotherapy, are more durable than those seen with cetuximab plus chemotherapy. The US Food and Drug Administration (FDA) has approved the use of pembrolizumab for this indication for all patients, along with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and as a single agent for those whose tumors express PD-L1 CPS ≥1  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). When given as a single agent or in combination, pembrolizumab is administered for a maximum of two years.</p><p>The use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) as second-line therapy is discussed separately. (See <a class="local">'PD-1 inhibitor immunotherapy'</a> below.)</p><p>In an open-label phase 3 trial (KEYNOTE-048, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fsearch%3Fterm%3DNCT02358031&amp;token=nbsXe3i4qfUea5RCPRHtOZSam2H1CiUIdLOcQ7NLb3iKeJkihmim1YanHtZx4iX83hLiXL5zDSJH7yM%2BpBLavQ%3D%3D&amp;TOPIC_ID=3364" target="_blank">NCT02358031</a>), 882 patients with recurrent or metastatic squamous cell carcinoma of the head and neck not curable by surgery and without prior systemic therapy in the metastatic setting were randomly assigned on a 1:1:1 basis to receive single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> versus pembrolizumab plus a platinum and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> combination versus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus a platinum and fluorouracil combination [<a href="#rid52">52-54</a>]. PD-L1 status was assessed using CPS, which stains lymphocytes and other cells in addition to tumor cells. Results were evaluated for tumors with varying CPS scores and the entire study population regardless of CPS. </p><p>Pembrolizumab-containing combination therapy, in comparison with cetuximab-containing combination therapy, demonstrated the following:</p><p class="bulletIndent1"><span class="glyph">●</span>At median follow-up of 45 months, improved OS in the total study population (median 13 versus 11 months, four-year OS 19 versus 5 percent, hazard ratio [HR] 0.71, 95% CI 0.59-0.85) and in those with CPS ≥1 (median 14 versus 11 months, four-year OS 22 versus 4 percent, HR 0.64, 95% CI 0.53-0.78) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar ORRs (44 versus 38 percent for CPS ≥20, 37 versus 36 percent for CPS ≥1), but longer duration of response for pembrolizumab-based combination therapy [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar rates of grade ≥3 treatment-related adverse events between the treatment groups (72 versus 69 percent) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In post-hoc analyses by CPS subgroup, at median follow-up of approximately 33 months [<a href="#rid53">53</a>] and 45 months [<a href="#rid54">54</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS in patients with CPS ≥20 (median 15 versus 11 months, HR 0.62, 95% CI 0.46-0.84) [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS in patients with CPS between 1 and 19 (median 13 versus 10 months, HR 0.71, 95% CI 0.54-0.94) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar OS in those with CPS &lt;1 (11.3 versus 10.7 months, HR 1.21, 95% CI 0.76-1.94) [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar progression-free survival (PFS) in patients with CPS ≥20 (median 6 versus 5 months, HR 0.76, 95% CI 0.57-1.02) [<a href="#rid54">54</a>], those with CPS between 1 and 19 (median 4.9 months each, HR 0.93, 95% CI 0.71-1.21), and those with CPS &lt;1 (median 5 versus 6 months, HR 1.46, 95% CI 0.93-2.3) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar ORRs for patients with CPS between 1 and 19 (29 versus 33 percent) and those with CPS &lt;1 (31 versus 39 percent) [<a href="#rid53">53</a>]. </p><p></p><p>Single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, in comparison with cetuximab-containing combination therapy, demonstrated the following:</p><p class="bulletIndent1"><span class="glyph">●</span>At median follow-up of 45 months, improved OS in the total study population (median 12 versus 11 months, four-year OS 15 versus 7 percent, HR 0.81, 95% CI 0.68-0.97) and in those with CPS ≥1 (median OS 12 versus 10 months, four-year OS 17 versus 6 percent, HR 0.74, 95% CI 0.61-0.89) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower PFS in the total population (median 2 versus 5 months, HR 1.29, 95% CI 1.09-1.53), with more early progression in the <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> arm [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower ORRs in the total population (17 versus 36 percent), but longer duration of response in all populations [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer grade ≥3 treatment-related adverse events (17 versus 69 percent) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In post-hoc analyses by CPS subgroup, at median follow-up of approximately 33 months [<a href="#rid53">53</a>] and 45 months [<a href="#rid54">54</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS in patients with CPS ≥20 (median 15 versus 11 months, HR 0.61, 95% CI 0.46-0.81) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar OS in patients with CPS between 1 and 19 (median 11 versus 10 months, HR 0.86, 95% CI 0.66-1.12) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower OS in patients with CPS &lt;1, although the results were not statistically significant (median 8 versus 11 months, HR 1.51, 95% CI 0.96-2.37) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar PFS in patients with CPS ≥20 (median 3 versus 5 months, HR 0.96, 95% CI 0.74-1.26) [<a href="#rid54">54</a>], those with CPS between 1 and 19 (2 versus 5 months, HR 1.25, 95% CI 0.96-1.61), and lower PFS for those with CPS &lt;1 (median 2 versus 6 months, HR 4.31, 95% CI 2.63-7.08) [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower ORRs for patients with CPS between 1 and 19 (15 versus 34 percent) and those with CPS &lt;1 (5 versus 42 percent) [<a href="#rid53">53</a>]. </p><p></p><p class="headingAnchor" id="H756953886"><span class="h2">Pembrolizumab with platinum plus taxane</span><span class="headingEndMark"> — </span>For patients treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy, some contributors prefer a chemotherapy regimen that includes platinum plus a taxane (such as <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) rather than regimens that include platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>. Pembrolizumab plus <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and paclitaxel is active in clinical studies of recurrent and metastatic head and neck cancer [<a href="#rid56">56</a>]. In addition, regimens that contain platinum with a taxane are similarly effective and better tolerated than regimens containing platinum plus fluorouracil [<a href="#rid57">57</a>]. (See <a class="local">'Cetuximab with platinum-based chemotherapy'</a> below.)</p><p>In a phase IV trial (KEYNOTE-B10), 92 patients with treatment-naïve recurrent or metastatic head and neck cancer were treated with up to six cycles of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> in combination with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid56">56</a>]. Pembrolizumab monotherapy was subsequently continued to complete up to a total of 35 cycles. In preliminary results, at median follow-up of eight months, the ORR for the entire study population was 48 percent, including a complete response rate of 5 percent. Median PFS and OS for all patients were 6 and 12 months, respectively. The grade ≥3 toxicity rate was 71 percent, including two deaths attributed to sepsis and hypersensitivity reaction.</p><p class="headingAnchor" id="H175776916"><span class="h2">Cetuximab with platinum-based chemotherapy</span><span class="headingEndMark"> — </span>For patients who have a good performance status but are not eligible for immunotherapy, the combination of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> with <strong>either</strong> a platinum and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> <strong>or</strong> a platinum plus a taxane are both options for initial therapy of advanced squamous cell carcinoma of the head and neck  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). We prefer the use of cetuximab in combination with a platinum plus a taxane, which confers similar efficacy but less toxicity relative to cetuximab in combination with a platinum plus fluorouracil.</p><p><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The addition of cetuximab to a platinum-based doublet regimen increases OS compared with doublet chemotherapy alone. Cetuximab is approved for first-line use in combination with platinum-based chemotherapy. <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a> in combination with a platinum and cetuximab demonstrates a similar survival benefit and less toxicity relative to <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> with a platinum and cetuximab [<a href="#rid57">57</a>].</p><p>Of note, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> is administered either weekly or every two weeks, in combination with a platinum and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>. Clinicians may offer cetuximab on an every-two-week schedule as a convenient and alternative dosing to the weekly schedule, both of which have approval from the FDA in patients with squamous cell carcinoma of the head and neck [<a href="#rid58">58</a>]. If the every-two-week schedule of cetuximab  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) is chosen in this setting, our general approach is to reserve its use for the maintenance phase of therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cetuximab</strong><strong> with platinum and </strong><strong>fluorouracil</strong> – In the phase III EXTREME trial, 442 patients with recurrent or metastatic squamous cell carcinoma of the head and neck were assigned to a platinum (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> 100 mg/m<sup>2</sup> on day 1 or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> area under the concentration x time curve [AUC] 5 day 1) plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (1000 mg/m<sup>2</sup> per day for four days) every three weeks, with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> (400 mg/m<sup>2</sup> for the initial dose, followed by subsequent weekly 250 mg/m<sup>2</sup>) [<a href="#rid25">25</a>]. Overall, 39 percent of patients had received systemic cytotoxic chemotherapy at least six months prior to randomization as part of their initial definitive management. Chemotherapy was given for a maximum of six cycles, although cetuximab could be continued as maintenance therapy until disease progression or toxicity. Crossover to include cetuximab was not allowed in the chemotherapy arm of the trial.</p><p></p><p class="bulletIndent1">Chemotherapy plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> significantly prolonged OS compared with chemotherapy alone (median 10.1 versus 7.4 months, HR for death 0.80, 95% CI 0.64-0.99). Significant improvements were also seen in the PFS and objective response rates (median 5.6 versus 3.3 months and 36 versus 20 percent, respectively). In a retrospective analysis of the trial, the improvements seen with cetuximab appeared to be similar in those whose tumor was human papillomavirus (HPV) related compared with those whose tumor was HPV negative [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">Crossover was not allowed. Thus, this trial does not exclude the possibility that sequential use of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> followed by <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> at the time of failure would be equivalent in survival with the three-drug regimen.</p><p></p><p class="bulletIndent1">The overall incidence of severe (grade 3 or 4) adverse events with the <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> regimen was not significantly increased compared with chemotherapy alone (82 versus 76 percent). However, treatment with cetuximab resulted in a significant increase in the incidence of severe hypomagnesemia (5 versus 1 percent), severe skin reactions (9 versus &lt;1 percent), and sepsis (4 versus &lt;1 percent). Severe infusion-related reactions to cetuximab occurred in 3 percent of cases. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cetuximab</strong><strong> with platinum and taxane</strong> – In an open-label phase II trial, 541 patients with recurrent or metastatic disease were randomly assigned to six cycles of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> versus four cycles of cisplatin and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus cetuximab [<a href="#rid57">57</a>]. Both regimens were followed by maintenance cetuximab.</p><p></p><p class="bulletIndent1">At a median follow-up of 34 months (among the 539 patients included in the intention-to-treat analysis), relative to the fluorouracil-based regimen, the docetaxel-based regimen demonstrated similar OS (median 14.5 versus 13.4 months; HR 0.91, 95% CI 0.75-1.10), decreased toxicity (grade ≥3 adverse events 81 versus 93 percent), less delays in administration (10 versus 27 percent), less substitution of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> for <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (6 versus 25 percent), and a higher percentage of patients initiating maintenance <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> (72 versus 52 percent).</p><p></p><p class="headingAnchor" id="H2003234733"><span class="h2">Combination chemotherapy</span><span class="headingEndMark"> — </span>A number of combination chemotherapy regimens without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> have been evaluated in patients with advanced head and neck cancer, most of which include a platinum compound  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). Although these regimens significantly improve response rates compared with a single agent, an improvement in OS has not been demonstrated compared with single-agent chemotherapy.</p><p class="headingAnchor" id="H1639150675"><span class="h3">Platinum and fluorouracil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> (100 mg/m<sup>2</sup> intravenous, day 1) and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (1000 mg/m<sup>2</sup> per day, continuous infusion, for four days) is a standard combination chemotherapy regimen for use in the palliative setting. In phase III trials, this regimen produced response rates around 30 percent, which is significantly better than with single-agent cisplatin or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid1">1,2,16,60</a>].</p><p>As an example, a Southwest Oncology Group (SWOG) trial randomly assigned 261 patients with advanced head and neck cancer to one of three regimens: <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus fluorouracil, or single-agent <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid1">1</a>]. The overall response rate was greater for the two combination regimens compared with methotrexate (32 and 21 versus 10 percent, respectively). However, the median survival was similar with all three regimens (6.6, 5.0, and 5.6 months, respectively). The percentage of patients with any grade 3 or 4 toxicity was greatest for those treated with the cisplatin regimen compared with the carboplatin regimen or single-agent methotrexate (33 versus 26 and 16 percent, respectively).</p><p>Because of the toxicity of this regimen and the need for prolonged infusion, we often prefer to use a platin plus taxane combination or single agents as first-line treatment in the palliative setting.</p><p class="headingAnchor" id="H340750992"><span class="h3">Platinum plus taxane</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> have been combined with either <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> in various combination regimens. None of these regimens have demonstrated superiority compared with cisplatin plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>.</p><p>The most extensive data on the role of a platinum-taxane regimen come from a phase III trial conducted by the ECOG, in which 204 patients were randomly assigned to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> or cisplatin plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid60">60</a>]. With a median follow-up of eight months, there were no statistically significant differences in OS (median survival 8.7 versus 8.1 months and one-year survival rate 41 versus 32 percent) or objective response rate (27 versus 26 percent). Gastrointestinal and hematologic toxicities were more common in patients receiving cisplatin plus fluorouracil.</p><p>Combinations of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (75 to 100 mg/m<sup>2</sup>) plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (70 to 75 mg/m<sup>2</sup>) given every three weeks have been evaluated in phase II studies that included both previously treated and chemotherapy-naïve patients. Overall response rates ranged from 32 to 55 percent, with median response durations around five months [<a href="#rid61">61-64</a>]. These higher response rates were associated with severe side effects in up to 70 percent of patients. Weekly therapy with this combination may have similar efficacy and a more favorable toxicity profile [<a href="#rid65">65</a>]. Docetaxel plus cisplatin has not been compared with cisplatin plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> in a randomized phase III trial.</p><p>The substitution of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> for <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> simplifies administration and is associated with less nephrotoxicity, neurotoxicity, ototoxicity, and emesis. Carboplatin has also been combined with either <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> in phase II trials [<a href="#rid66">66-68</a>]. These combinations have not been adequately assessed in randomized trials.</p><p class="headingAnchor" id="H1943184606"><span class="h3">Non-platinum-based regimens</span><span class="headingEndMark"> — </span>Other combinations, such as <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> and paclitaxel plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, may be useful in patients who are not candidates for platinum-based chemotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong><strong> plus </strong><strong>paclitaxel</strong> – In a SWOG study in 57 patients with metastatic or recurrent head and neck cancer, the combination of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> (3000 mg/m<sup>2</sup>) plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> (150 mg/m<sup>2</sup>) on days 1 and 15 of 28-day cycles was associated with a 28 percent objective response rate [<a href="#rid69">69</a>]. Median PFS and OS were four and eight months, respectively. However, it is not clear if this is superior to single-agent taxane therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paclitaxel</strong><strong> plus </strong><strong>cetuximab</strong> – In an open-label phase II trial, the combination of weekly <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> resulted in a response rate of 54 percent and median PFS and OS of approximately four and eight months [<a href="#rid70">70</a>]. The efficacy of this regimen is consistent with other doublet regimens.</p><p></p><p class="headingAnchor" id="H3332011710"><span class="h2">Regimens not used</span><span class="headingEndMark"> — </span>Certain regimens are not offered as initial therapy for recurrent or metastatic head and neck cancer either due to a lack of OS benefit in randomized trials and/or significant toxicity. </p><p>Chemotherapy regimens that we do not offer include <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid43">43</a>] and various three- or four-drug chemotherapy regimens such as <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, cisplatin, and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [<a href="#rid71">71-73</a>]; <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, cisplatin, and fluorouracil [<a href="#rid74">74,75</a>]; <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and cisplatin [<a href="#rid76">76</a>]; and paclitaxel, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, and cisplatin or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid77">77,78</a>].</p><p>Targeted therapies that are not used include <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> or <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, as the addition of these agents to chemotherapy failed to improve OS in separate randomized trials [<a href="#rid79">79,80</a>]. These agents should <strong>not</strong> be substituted for <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>. </p><p>We also do not offer <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, as this combination of immune checkpoint inhibitors (ICIs) failed to improve OS over chemotherapy with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus platinum-based chemotherapy in a randomized phase III trial (CheckMate 651) [<a href="#rid81">81</a>]. Similarly, in a separate randomized phase II trial (CheckMate 714), initial therapy with nivolumab plus ipilimumab did not improve objective response rates over single-agent nivolumab [<a href="#rid82">82</a>]. </p><p class="headingAnchor" id="H23915954"><span class="h1">PREVIOUS SYSTEMIC THERAPY FOR LOCOREGIONAL DISEASE</span></p><p class="headingAnchor" id="H1009103257"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>Concurrent and/or induction chemotherapy is frequently used in combination with radiation therapy (RT) for definitive therapy in patients who present with locoregional disease. Although such treatment has the potential to cure some patients, many relapse, either with recurrent disease in the head and neck region or with distant metastases. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p>Some patients who relapse may be candidates for salvage therapy with curative intent, using either surgery or reirradiation. However, most patients who recur ultimately require palliative systemic therapy. The optimal regimen for these patients has not been defined. (See  <a class="medical medical_review" href="/z/d/html/3373.html" rel="external">"Treatment of locally recurrent squamous cell carcinoma of the head and neck"</a>.)</p><p>Key factors that need to be considered in choosing a treatment include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Original chemotherapy exposure and drugs (either concurrent or induction)</p><p class="bulletIndent1"><span class="glyph">●</span>Response to the initial chemotherapy or chemoradiation regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Interval between initial treatment and disease progression</p><p class="bulletIndent1"><span class="glyph">●</span>Patient performance status and comorbidities</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to immunotherapy</p><p></p><p>Patients with progression after initial definitive therapy that included concurrent and/or induction chemotherapy in combination with RT can be treated with immunotherapy-based regimens, in some cases similarly to previously untreated patients  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short period of disease control</strong> – For most patients with a relatively short period of disease control (less than six months) from initial definitive treatment that included platinum-based chemotherapy, we offer single-agent immunotherapy rather than single-agent or combination therapy with a platinum, taxane, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>), or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Chemotherapy is unlikely to offer sustained benefit in this population due to a high likelihood of chemotherapy resistance. Clinical trial options should also be considered. (See <a class="local">'PD-1 inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged period of disease control</strong> – For patients with a relatively prolonged period of disease control (greater than or equal to six months) following initial definitive treatment that included platinum-based chemotherapy, we offer <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with or without platinum-based chemotherapy. <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> is the preferred platinum for patients who have already received <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. The approach is similar to previously untreated patients.</p><p></p><p>The KEYNOTE-048 trial, which evaluated these options in previously untreated patients, allowed enrollment of patients who had received definitive locoregional therapy prior to recurrence, as long as they had not received prior systemic therapy in the recurrent/metastatic setting. This is described in more detail separately. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above.)</p><p class="headingAnchor" id="H15"><span class="h1">SUBSEQUENT THERAPY</span></p><p class="headingAnchor" id="H3336476303"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>Many patients who receive systemic therapy for metastatic or recurrent head and neck cancer ultimately relapse. The choice of subsequent therapy is evolving. There is no agreed-upon standard of care, and experts differ in their preferred approach. Additionally, as immunotherapy regimens become standard in the first-line setting, optimal second-line regimens become less clear. As such, clinical trials are often appropriate.</p><p>Options outside of a clinical trial include immunotherapy, cytotoxic chemotherapy, and targeted agents in various combinations. The choice of treatment regimen is influenced by prior treatment history, performance status and comorbidities, and the potential toxicities of a proposed regimen. Symptom-directed care also plays an important role in the management of these patients.</p><p>We suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with progression following initial treatment with systemic platinum-based chemotherapy (with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>) <strong>and who are eligible</strong> for immunotherapy, we offer immunotherapy with a programmed death protein 1 (PD-1) antibody (<a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>)). (See <a class="local">'PD-1 inhibitor immunotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those patients with progression following initial treatment with systemic platinum-based chemotherapy (with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>) <strong>and who are</strong> <strong>ineligible</strong> for immunotherapy, options include single-agent cetuximab  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) if not previously received; taxanes  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>) if not previously received; a platinum for patients with disease progression more than six months after prior platinum-based chemotherapy (preferably <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> if prior <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> exposure); <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>; or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. (See <a class="local">'Cytotoxic chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with progression on immunotherapy alone <strong>and</strong> no prior exposure to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, we suggest the combination of a platinum plus a taxane or a platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, with or without the use of cetuximab [<a href="#rid83">83</a>]. Although the addition of cetuximab increases overall survival (OS) when added to a platinum plus fluorouracil as first-line therapy in recurrent/metastatic squamous cell carcinoma of the head and neck, there is no evidence that this is more effective than using cetuximab sequentially as second-line therapy. (See <a class="local">'Cetuximab with platinum-based chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with progression on combination immunotherapy and platinum plus fluorouracil-based chemotherapy, we suggest either <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> alone  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) or cetuximab in combination with taxane-based chemotherapy [<a href="#rid54">54</a>]. Since these patients have progressed on chemotherapy, their tumors are likely to be chemotherapy resistant; therefore, the use of cetuximab may be warranted. (See <a class="local">'Cetuximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe comorbidities and/or a poor performance status may be best treated with supportive care and without initiating systemic therapy.</p><p></p><p class="headingAnchor" id="H2059899026"><span class="h2">PD-1 inhibitor immunotherapy</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) target programmed death protein 1 (PD-1) and have important clinical activity in patients with head and neck squamous cell carcinoma; both are approved by the US Food and Drug Administration (FDA) for patients who have previously been treated with platinum-based chemotherapy for metastatic or recurrent squamous cell carcinoma the head and neck. The toxicity associated with these agents is similar to that observed with their use in other indications. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H910811897"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">Pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) is a PD-1 inhibitor that has demonstrated activity in previously treated patients. In prospective trials, objective responses have been reported in 15 to 18 percent, with the majority of responses lasting more than six months. It has demonstrated a modest survival benefit, with less toxicity when compared with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). The use of pembrolizumab in previously untreated patients is discussed separately. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above.) </p><p>In an open-label, phase 3 clinical trial (KEYNOTE-040), 495 patients who had failed prior platinum therapy were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> or standard of care (investigator's choice of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>)) [<a href="#rid10">10</a>]. Immune checkpoint inhibitors (ICIs) were allowed at the time of progression in any treatment group and were more commonly used in those assigned to the standard of care group (13 versus 5 percent). The following were reported with a median follow-up over seven months:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> had fewer adverse events (63 versus 84 percent) but more immune-related toxicity (eg, hypothyroidism, pneumonitis). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although not statistically significant, more patients assigned to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> had tumor responses (15 versus 10 percent). These responses were more durable (median duration of response 18 versus 5 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the group as a whole, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> modestly improved OS (12-month survival 37 versus 27 percent, median survival 8.4 versus 6.9 months, hazard ratio [HR] 0.8, 95% CI 0.65-0.98).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prespecified exploratory analysis, the survival benefit was demonstrated in the 26 percent of patients who had programmed death ligand 1 (PD-L1) expression ≥50 percent (HR 0.53, 95% CI 0.35-0.81), whereas it was not statistically significant in those with PD-L1 expression &lt;50 percent (HR 0.93, 95% CI 0.73-1.17).</p><p></p><p>These results support the use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in this population, especially among those with high PD-L1 expression. Further data regarding the activity of pembrolizumab come from two large, nonrandomized studies in previously treated patients:</p><p class="bulletIndent1"><span class="glyph">●</span>In the KEYNOTE-012 study, 192 patients were treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> on one of two schedules: 10 mg/kg every two weeks or a fixed dose of 200 mg every three weeks [<a href="#rid8">8,11,84,85</a>]. This was a heavily pretreated population with 45 percent having received at least three prior therapies. Objective responses were observed in 34 patients (18 percent). The response rate was similar in human papillomavirus (HPV)-positive and HPV-negative patients. Responses lasted ≥6 months in 85 percent (range 2+ to 30+ months), and OS at 12 months was 38 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the KEYNOTE-055 study, 171 patients were treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> 200 mg every three weeks [<a href="#rid86">86</a>]. All patients had platinum- and cetuximab-refractory head and neck cancer. The objective response rate was 16 percent, and the median duration of response was eight months. Response rates were similar in patients who were HPV positive and HPV negative, and in the various PD-L1 subgroups.</p><p></p><p>In both trials, the toxicity was similar to that reported with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in other indications, except for a higher incidence of hypothyroidism (15 percent). (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H3210750184"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) is a PD-1 inhibitor that has demonstrated activity in previously treated patients, including those with prior <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) exposure. In one prospective trial, objective responses were seen in 13 percent, and nivolumab demonstrated a modest survival benefit with less toxicity when compared with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, or cetuximab  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>).</p><p>In the Checkmate-141 phase 3 trial, 361 patients with platinum-refractory, recurrent or metastatic disease were randomly assigned to either <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg every two weeks) or a single-agent investigator's choice of therapy (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>)) [<a href="#rid9">9,87-90</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>With a minimum follow-up of 11.4 months, OS for the entire study population was longer in patients treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> (median 7.7 versus 5.1 months, one-year survival rate 34 versus 19.7 percent, HR 0.71, 95% CI 0.55-0.9). The objective response rate was also increased with nivolumab (13.3 versus 5.8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prespecified exploratory analysis, OS was increased with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> in patients with PD-L1 expression ≥1 percent (8.7 versus 4.6 months, HR 0.55, 95% CI 0.36-0.83). OS was not significantly increased in patients with PD-L1 expression &lt;1 percent (HR 0.89, 95% CI 0.54-1.45).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post hoc exploratory analysis, OS was increased in patients with HPV-positive tumors treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> (median 9.1 versus 4.4 months, HR 0.56, 95% CI 0.32-0.99). The difference in OS was not statistically significant in those with HPV-negative tumors (median 7.5 versus 5.8 months, HR 0.73, 95% CI 0.42-1.25).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a> was not routinely available for those patients randomized to chemotherapy, and routine use of nivolumab after second-line chemotherapy could negate or minimize the survival benefit of immediate nivolumab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent post hoc exploratory analysis, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> improved OS among those without prior <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> exposure (median 8.2 versus 4.9 months, HR 0.52, 95% CI 0.35-0.77) [<a href="#rid90">90</a>]. For those with prior cetuximab exposure, OS with nivolumab was similar to that seen with chemotherapy (median OS 7.1 versus 5.1 months, HR 0.84, 95% CI 0.62-1.15). Among those treated with nivolumab, estimated 12-month OS was similar, regardless of previous cetuximab exposure (39 and 31 percent for those without or with cetuximab exposure, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient-reported outcomes on a quality of life questionnaire found that there was no clinically meaningful deterioration associated with treatment with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, in contrast to chemotherapy, where quality of life significantly decreased in 8 of 15 domains [<a href="#rid87">87</a>].</p><p></p><p>Based on the results of this phase 3 trial, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) was approved by the FDA [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H3292227297"><span class="h3">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Durvalumab</strong><strong> with or without </strong><strong>tremelimumab</strong> – <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">Durvalumab</a>, a PD-L1 inhibitor, does not have an established role as subsequent therapy in patients with recurrent or metastatic disease. While durvalumab showed initial clinical activity in a phase II study [<a href="#rid92">92</a>], it failed to improve OS compared with standard chemotherapy in randomized phase III trials, either as a single agent or in combination with the CTLA-4 inhibitor <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">tremelimumab</a> [<a href="#rid93">93,94</a>].</p><p></p><p class="headingAnchor" id="H23915983"><span class="h2">Cytotoxic chemotherapy</span><span class="headingEndMark"> — </span>For patients who are candidates for further lines of cytotoxic chemotherapy, the choice of agent is based on prior treatment history and the overall condition of the patient. Patients who receive ICIs as part of initial therapy may demonstrate increased tumor sensitivity to subsequent-line chemotherapy [<a href="#rid54">54,95</a>]. For patients who progress through initial chemotherapy alone, objective responses to subsequent lines of single-agent cytotoxic chemotherapy are uncommon, particularly when contemporary response criteria are applied. There is no evidence that single-agent chemotherapy prolongs OS. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong><strong> </strong>– The limited activity of single-agent <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> in this setting is illustrated by a phase III trial that compared weekly intravenous methotrexate with <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in a heavily pretreated population [<a href="#rid36">36</a>]. Among the 152 patients treated with methotrexate, the overall response rate was 4 percent, and the median OS was seven months [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platinum and taxanes</strong> – Other single agents, such as <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>), have produced higher response rates than <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> in randomized trials, but this has generally been associated with increased toxicity. </p><p></p><p class="bulletIndent1">One randomized trial (KEYNOTE-048) suggested a treatment benefit with taxanes in patients initially treated with ICI-based regimens [<a href="#rid54">54</a>]. However, these agents have not been shown to affect OS in patients who progress on chemotherapy alone [<a href="#rid14">14-16,26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> has also shown evidence of activity in several observational studies and may represent a single-agent option for some previously treated patients [<a href="#rid37">37,38</a>].</p><p></p><p>Toxicity profiles for different chemotherapy agents vary widely and may be an important consideration when choosing a regimen. As an example, single-agent <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> causes more mucositis than <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, but less nausea or vomiting [<a href="#rid14">14</a>]. When weekly <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> was compared with methotrexate, docetaxel was associated with grade 3 or 4 neutropenia (13 percent), febrile neutropenia (1 percent), anemia (19 percent), mucositis (9 percent), and ungual (nail) toxicity (pain and ungual loss, 9 percent), whereas methotrexate was associated with grade 3 or 4 anemia (15 percent) and mucositis (5 percent) [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H23915990"><span class="h2">Cetuximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is overexpressed in most squamous head and neck cancers. The activity of cetuximab in patients refractory to platinum-based chemotherapy has been demonstrated in several multicenter phase II trials, all of which observed an objective response rate of approximately 10 percent [<a href="#rid45">45,96,97</a>]. It appears to be effective, with approximately the same rate of benefit regardless of prior therapy. (See  <a class="medical medical_review" href="/z/d/html/85694.html" rel="external">"Treatment protocols for squamous cell carcinoma of the head and neck"</a>.)</p><p><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> is administered as monotherapy either weekly or every two weeks  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). Clinicians may offer cetuximab on an every-two-week schedule as a convenient and alternative dosing to the weekly schedule, both of which have approval from the FDA in squamous cell carcinoma of the head and neck [<a href="#rid58">58</a>]. The standard schedule for cetuximab is 250 mg/m<sup>2</sup> weekly, and further dose escalation does not appear to be beneficial. Another study in 35 patients evaluated cetuximab at a dose of 500 mg/m<sup>2</sup> every two weeks; treatment was well tolerated and had similar efficacy (response rate 11 percent) [<a href="#rid98">98</a>]. Further dose escalation (750 mg/m<sup>2</sup>) on the every-two-week schedule did not result in any improvement in efficacy in another 26 patients (response rate 8 percent).</p><p>The activity of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> is illustrated by a series of 103 patients with progressive disease following two to six cycles of platinum-based therapy [<a href="#rid45">45</a>]. Cetuximab was given with an initial dose of 400 mg/m<sup>2</sup>, followed by 250 mg/m<sup>2</sup> weekly. Overall, 17 patients (13 percent) had an objective response, including 8 of 79 (10 percent) who had had progression with the <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy and 9 of 51 (18 percent) who had had stable disease. The median survival from the initiation of cetuximab therapy was 7.5 months.</p><p class="headingAnchor" id="H1162435504"><span class="h1">INVESTIGATIONAL APPROACHES</span></p><p class="headingAnchor" id="H3156707794"><span class="h2">Farnesyltransferase inhibitors</span><span class="headingEndMark"> — </span>In patients with heavily pretreated <em>HRAS</em> mutant squamous cell carcinoma of the head and neck, the farnesyltransferase inhibitor tipifarnib demonstrated objective response rates of up to 56 percent in phase II trials [<a href="#rid99">99</a>]. These data are encouraging, and further studies are necessary before incorporating this approach into routine clinical practice. The use of farnesyltransferase inhibitors in head and neck and salivary gland tumors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations", section on 'Ras-mediated pathway: Raf/MEK/ERK and PI3K'</a> and  <a class="medical medical_review" href="/z/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'Investigational agents'</a>.)</p><p class="headingAnchor" id="H2506925762"><span class="h2">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cetuximab</strong><strong>-based combination regimens</strong> – Various cetuximab-based combination regimens are being investigated in treatment-refractory recurrent or metastatic head and neck cancer. These include <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid100">100</a>], <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus cetuximab [<a href="#rid101">101</a>], and ficlatuzumab plus cetuximab [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metronomic chemotherapy </strong>– Metronomic chemotherapy uses frequent, lower doses of chemotherapy over long periods of time to target tumor angiogenesis and minimize toxicity. Metronomic chemotherapy has been evaluated as initial and subsequent-line therapy in resource-limited areas [<a href="#rid103">103,104</a>]. This approach remains investigational. </p><p></p><p class="bulletIndent1">The addition of low-dose <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> to metronomic chemotherapy (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> with <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> and <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>) improved OS in a randomized phase III trial of patients with recurrent or newly diagnosed advanced head and neck cancer [<a href="#rid104">104</a>]. Initial reports also suggest that oral metronomic chemotherapy is active and well tolerated in patients with platinum-resistant disease [<a href="#rid103">103</a>], although this approach has not been evaluated in those receiving prior immunotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palbociclib</strong><strong> </strong>– The clinical role of <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a>, a cyclin-dependent kinase (CDK) inhibitor specific to CDK4 and CDK6, remains investigational in patients with recurrent or metastatic head and neck squamous cell carcinoma. Palbociclib has been evaluated in combination with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> in patients with HPV negative disease resistant to platinum and/or cetuximab [<a href="#rid105">105-107</a>]. While initial trials suggested that palbociclib plus cetuximab could potentially reverse previous cetuximab resistance [<a href="#rid106">106</a>], a randomized phase II trial (PALATINUS) demonstrated that this combination did not improve OS in patients with platinum-resistant disease [<a href="#rid107">107,108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small molecule tyrosine kinase inhibitors</strong> – A number of small molecule tyrosine kinase inhibitors have been tested in patients with advanced head and neck cancer, including <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a>, and tivantinib. No clear clinical role has yet been established for this approach [<a href="#rid32">32,34-36,109-112</a>].</p><p></p><p class="bulletIndent1">Large phase III trials have compared two EGFR inhibitors, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> and <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, both alone and in combination with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, with standard chemotherapy [<a href="#rid36">36,110,111,113</a>]. None of these have demonstrated a significant increase in OS.</p><p></p><p class="headingAnchor" id="H3054570022"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H71093423"><span class="h2">High tumor mutational burden</span><span class="headingEndMark"> — </span>The management of patients with recurrent or metastatic head and neck cancer whose tumors express high levels of tumor mutational burden is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p class="headingAnchor" id="H3547308221"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H3593955569"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83256.html" rel="external">"Patient education: Throat cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>– The management of patients with no prior systemic therapy for recurrent or metastatic squamous cell carcinoma of the head and neck is influenced by prior initial treatment for locoregional disease, performance status, comorbidities, tissue programmed death ligand 1 (PD-L1) combined positive score (CPS), and related prognostic factors. (See <a class="local">'General approach'</a> above and <a class="local">'Previously untreated patients'</a> above.)</p><p></p><p class="bulletIndent1">Multiple active systemic agents are available, including chemotherapy, immune checkpoint inhibitors (ICIs), and targeted therapy such as <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). (See <a class="local">'Active agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall survival benefit for immunotherapy plus chemotherapy </strong>– Immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) improves overall survival (OS) compared with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus chemotherapy. For those with a high CPS, single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) also improves OS compared with cetuximab plus chemotherapy. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No prior systemic therapy,</strong> <strong>CPS &lt;1 or unavailable</strong> – For patients with no prior systemic therapy for recurrent or metastatic disease, and who have a PD-L1 CPS of &lt;1 or unavailable, we suggest platinum-based chemotherapy, with or without <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, rather than other chemotherapy regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). (See <a class="local">'Selection of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those in whom <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is not used, concurrent or sequential <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) with combination chemotherapy (platinum with either <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> or taxane) is a reasonable alternative. (See <a class="local">'Cetuximab with platinum-based chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who are not eligible for combination chemotherapy and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, options include single-agent therapy with a platinum (typically <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>), taxanes (eg, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>), <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>). (See <a class="local">'Active agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No prior systemic therapy,</strong> <strong>CPS ≥1 </strong>– For patients with no prior systemic therapy for recurrent or metastatic disease who have PD-L1 CPS ≥1, we recommend pembrolizumab-based therapy rather than <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus chemotherapy or chemotherapy alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef111698" href="/z/d/graphic/111698.html" rel="external">algorithm 1</a>). For those who are eligible for combination therapy but have a contraindication to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, options include a doublet cytotoxic chemotherapy regimen, with or without cetuximab. (See <a class="local">'Selection of therapy'</a> above.)</p><p></p><p class="bulletIndent1">When using pembrolizumab-based therapy, our approach is dependent on the rapidity of tumor progression and PD-L1 CPS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with rapidly progressive disease</strong> – For patients with rapidly progressive disease who are eligible for combination chemotherapy plus immunotherapy, we suggest <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with a platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) rather than pembrolizumab alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), regardless of CPS. Alternatively, some contributors substitute a taxane (<a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) for the fluorouracil. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above and <a class="local">'Pembrolizumab with platinum plus taxane'</a> above.)</p><p></p><p class="bulletIndent2">However, for patients who are not eligible for combination therapy, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) is an appropriate alternative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without rapidly progressive disease</strong> – For most patients without rapidly progressive disease, our preferred regimen depends on the tissue CPS, as follows (see <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above and <a class="local">'Pembrolizumab with platinum plus taxane'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CPS ≥20</strong> – We suggest single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) rather than pembrolizumab plus chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CPS ≥1 and &lt;20</strong> – For patients with a good performance status (eg, Eastern Cooperative Oncology Group [ECOG] performance status ≤2  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>)), we suggest <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with platinum-based chemotherapy  (<a class="graphic graphic_table graphicRef139923" href="/z/d/graphic/139923.html" rel="external">table 6</a>) rather than single-agent pembrolizumab (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While chemotherapy regimens containing platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> are preferred, some contributors alternatively substitute a taxane (<a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) for the fluorouracil. </p><p></p><p class="bulletIndent3">For those with a lesser performance status where it is preferred to avoid the potential toxicities of systemic chemotherapy, single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is a reasonable alternative  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior systemic therapy for locoregional disease</strong> – For patients with no prior systemic therapy for recurrent or metastatic disease who previously received initial systemic therapy for locoregional disease with a platinum-based regimen (with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>) and are eligible for combination therapy, treatment suggestions are based on duration of disease control. (See <a class="local">'Previous systemic therapy for locoregional disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short period of</strong> <strong>disease control </strong>– For most patients with a relatively short period of disease control (&lt;6 months), we suggest immunotherapy with a PD-1 antibody (ie, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>)) rather than single-agent or combination therapy with a platinum, taxane, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>), or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Further chemotherapy is unlikely to offer sustained benefit in this population due to a high likelihood of chemotherapy resistance. Inclusion in a formal clinical trial is an appropriate alternative. (See <a class="local">'PD-1 inhibitor immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolonged period of</strong> <strong>disease control </strong>– For patients with a relatively prolonged period of disease control (≥6 months), we offer <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, with or without platinum-based chemotherapy, similar to the approach for previously untreated patients. <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> is the preferred platinum for patients who have already received <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'Pembrolizumab with or without platinum and fluorouracil'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong> – For patients who relapse after receiving prior systemic therapy for metastatic or recurrent disease, the choice of subsequent regimens is based on previous systemic therapy exposure(s), performance status, and comorbidities (see <a class="local">'Subsequent therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progression following initial treatment with systemic platinum-based chemotherapy (with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>) <strong>and who are eligible</strong> for immunotherapy, we suggest immunotherapy with a PD-1 antibody (<a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>)) rather than further lines of chemotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'PD-1 inhibitor immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progression following initial treatment with systemic platinum-based chemotherapy (with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>)<strong> and who are ineligible</strong> for immunotherapy, options include single-agent cetuximab if not previously received  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>); taxanes  (<a class="graphic graphic_table graphicRef139515" href="/z/d/graphic/139515.html" rel="external">table 4</a>) if not previously received; a platinum for patients with disease progression more than six months after prior platinum-based chemotherapy (preferably <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> if previous <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> exposure); <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>; or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. (See <a class="local">'Active agents'</a> above and <a class="local">'Cytotoxic chemotherapy'</a> above and <a class="local">'Cetuximab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progression on immunotherapy alone<strong> and</strong> no prior exposure to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, options include combinations of a platinum plus a taxane or a platinum plus <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, with or without the use of cetuximab. (See <a class="local">'Cetuximab with platinum-based chemotherapy'</a> above and <a class="local">'Platinum and fluorouracil'</a> above and <a class="local">'Platinum plus taxane'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progression on combination immunotherapy and platinum plus fluorouracil-based chemotherapy, options include <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> alone  (<a class="graphic graphic_table graphicRef56253" href="/z/d/graphic/56253.html" rel="external">table 5</a>) or cetuximab in combination taxane-based chemotherapy. (See <a class="local">'Cetuximab'</a> above and <a class="local">'Cetuximab with platinum-based chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical trials</strong> – If available, patients may be enrolled in clinical trials at any time during their treatment course. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for supportive care</strong> – Patients with severe comorbidities and/or a poor performance status may be best treated with supportive care, without initiating systemic therapy. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Head and neck cancer'</a> and  <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245.</a></li><li><a class="nounderline abstract_t">Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257.</a></li><li><a class="nounderline abstract_t">Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15:283.</a></li><li><a class="nounderline abstract_t">Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 1991; 101:494.</a></li><li><a class="nounderline abstract_t">Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222.</a></li><li><a class="nounderline abstract_t">Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004; 22:262.</a></li><li><a class="nounderline abstract_t">Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19:1088.</a></li><li class="breakAll">Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s009lbl.pdf (Accessed on August 08, 2016).</li><li><a class="nounderline abstract_t">Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856.</a></li><li><a class="nounderline abstract_t">Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393:156.</a></li><li><a class="nounderline abstract_t">Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 2018; 119:153.</a></li><li><a class="nounderline abstract_t">Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13.</a></li><li><a class="nounderline abstract_t">Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409.</a></li><li><a class="nounderline abstract_t">Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983; 52:206.</a></li><li><a class="nounderline abstract_t">A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer 1990; 61:311.</a></li><li><a class="nounderline abstract_t">Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5:521.</a></li><li><a class="nounderline abstract_t">Veronesi A, Zagonel V, Tirelli U, et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 1985; 3:1105.</a></li><li><a class="nounderline abstract_t">Forastiere AA, Takasugi BJ, Baker SR, et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987; 19:155.</a></li><li><a class="nounderline abstract_t">Havlin KA, Kuhn JG, Myers JW, et al. High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study. Cancer 1989; 63:423.</a></li><li><a class="nounderline abstract_t">Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71:723.</a></li><li><a class="nounderline abstract_t">De Andrés L, Brunet J, López-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13:1493.</a></li><li><a class="nounderline abstract_t">Welkoborsky HJ, Bleier R, Wissen-Siegert I. [Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin]. Laryngorhinootologie 1992; 71:261.</a></li><li><a class="nounderline abstract_t">Ebeling O, Eckel HE, Volling P, et al. [Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up]. HNO 1994; 42:629.</a></li><li><a class="nounderline abstract_t">Eisenberger M, Hornedo J, Silva H, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986; 4:1506.</a></li><li><a class="nounderline abstract_t">Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116.</a></li><li><a class="nounderline abstract_t">Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40:2071.</a></li><li><a class="nounderline abstract_t">Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:533.</a></li><li><a class="nounderline abstract_t">Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol 1998; 21:482.</a></li><li><a class="nounderline abstract_t">Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270.</a></li><li><a class="nounderline abstract_t">Fury MG, Sherman EJ, Rao SS, et al. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2014; 25:689.</a></li><li><a class="nounderline abstract_t">Gedlicka C, Kornfehl J, Turhani D, et al. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer Invest 2006; 24:242.</a></li><li><a class="nounderline abstract_t">Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980.</a></li><li><a class="nounderline abstract_t">Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&amp;N Ca) (abstract #5331). J Clin Oncol 2005.</a></li><li><a class="nounderline abstract_t">Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:8418.</a></li><li><a class="nounderline abstract_t">Kirby AM, A'Hern RP, D'Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006; 94:631.</a></li><li><a class="nounderline abstract_t">Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27:1864.</a></li><li><a class="nounderline abstract_t">Raguse JD, Gath HJ, Bier J, et al. Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2005; 17:425.</a></li><li><a class="nounderline abstract_t">Catimel G, Vermorken JB, Clavel M, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:543.</a></li><li><a class="nounderline abstract_t">Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010; 102:1687.</a></li><li><a class="nounderline abstract_t">Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001; 85:649.</a></li><li><a class="nounderline abstract_t">Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011; 29:1140.</a></li><li><a class="nounderline abstract_t">Fury MG, Haque S, Stambuk H, et al. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2011; 117:795.</a></li><li><a class="nounderline abstract_t">Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer 2012; 118:4694.</a></li><li><a class="nounderline abstract_t">Huber MH, Lippman SM, Benner SE, et al. Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. Ann Oncol 1995; 6:83.</a></li><li><a class="nounderline abstract_t">Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171.</a></li><li><a class="nounderline abstract_t">Handy JR, Bremner RM, Crocenzi TS, et al. Expert Consensus Document on Pulmonary Metastasectomy. Ann Thorac Surg 2019; 107:631.</a></li><li><a class="nounderline abstract_t">Shiono S, Kawamura M, Sato T, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg 2009; 88:856.</a></li><li><a class="nounderline abstract_t">Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999; 6:572.</a></li><li><a class="nounderline abstract_t">Mochizuki T, Okumura S, Ishii G, et al. Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg 2010; 11:56.</a></li><li><a class="nounderline abstract_t">Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008; 72:398.</a></li><li><a class="nounderline abstract_t">McBride S, Sherman E, Tsai CJ, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2021; 39:30.</a></li><li><a class="nounderline abstract_t">Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915.</a></li><li><a class="nounderline abstract_t">Burtness B, Rischin D, Greil R, et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022; 40:2321.</a></li><li><a class="nounderline abstract_t">Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2023; 41:790.</a></li><li><a class="nounderline abstract_t">Yu Y, Zakeri K, Sherman EJ, Lee NY. Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048. JAMA Oncol 2022; 8:1216.</a></li><li><a class="nounderline abstract_t">Dzienis MR, Cundom JE, Fuentes CS, et al. Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol 2022; 33;7S.</a></li><li><a class="nounderline abstract_t">Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021; 22:463.</a></li><li class="breakAll">US Food and Drug Administration (FDA) Prescribing Label for Cetuximab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s277s280lbl.pdf (Accessed on April 14, 2021).</li><li><a class="nounderline abstract_t">Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014; 25:801.</a></li><li><a class="nounderline abstract_t">Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562.</a></li><li><a class="nounderline abstract_t">Schöffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10:119.</a></li><li><a class="nounderline abstract_t">Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20:1593.</a></li><li><a class="nounderline abstract_t">Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11:845.</a></li><li><a class="nounderline abstract_t">Baur M, Kienzer HR, Schweiger J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002; 94:2953.</a></li><li><a class="nounderline abstract_t">Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006; 116:613.</a></li><li><a class="nounderline abstract_t">Stathopoulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997; 33:1780.</a></li><li><a class="nounderline abstract_t">Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92:2334.</a></li><li><a class="nounderline abstract_t">Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007; 25:182.</a></li><li><a class="nounderline abstract_t">Malhotra B, Moon J, Kucuk O, et al. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 2014; 36:1712.</a></li><li><a class="nounderline abstract_t">Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23:1016.</a></li><li><a class="nounderline abstract_t">Worden FP, Moon J, Samlowski W, et al. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 2006; 107:319.</a></li><li><a class="nounderline abstract_t">Hussain M, Gadgeel S, Kucuk O, et al. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999; 86:2364.</a></li><li><a class="nounderline abstract_t">Benasso M, Ponzanelli A, Merlano M, et al. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol 2006; 45:168.</a></li><li><a class="nounderline abstract_t">Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000; 23:128.</a></li><li><a class="nounderline abstract_t">Baghi M, Hambek M, Wagenblast J, et al. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2006; 26:585.</a></li><li><a class="nounderline abstract_t">Okuno SH, Mailliard JA, Suman VJ, et al. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer 2002; 94:2224.</a></li><li><a class="nounderline abstract_t">Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16:1325.</a></li><li><a class="nounderline abstract_t">Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001; 91:1316.</a></li><li><a class="nounderline abstract_t">Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14:697.</a></li><li><a class="nounderline abstract_t">Argiris A, Li S, Savvides P, et al. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. J Clin Oncol 2019; 37:3266.</a></li><li><a class="nounderline abstract_t">Haddad RI, Harrington K, Tahara M, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 2023; 41:2166.</a></li><li><a class="nounderline abstract_t">Harrington KJ, Ferris RL, Gillison M, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncol 2023; 9:779.</a></li><li><a class="nounderline abstract_t">Cabezas-Camarero S, Cabrera-Martín MN, Merino-Menéndez S, et al. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. Oncologist 2021; 26:e1018.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17:956.</a></li><li><a class="nounderline abstract_t">Chow LQ, Haddad R, Gupta S, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016.</a></li><li><a class="nounderline abstract_t">Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol 2017; 35:1542.</a></li><li><a class="nounderline abstract_t">Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 2017; 18:1104.</a></li><li><a class="nounderline abstract_t">Gillison ML, Blumenschein G Jr, Fayette J, et al. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079.</a></li><li><a class="nounderline abstract_t">Haddad R, Concha-Benavente F, Blumenschein G Jr, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer 2019; 125:3208.</a></li><li><a class="nounderline abstract_t">Ferris RL, Licitra L, Fayette J, et al. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res 2019; 25:5221.</a></li><li class="breakAll">Nivolumab: US Food and Drug Administration (FDA) Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf (Accessed on February 20, 2023).</li><li><a class="nounderline abstract_t">Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer 2019; 107:142.</a></li><li><a class="nounderline abstract_t">Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol 2020; 31:942.</a></li><li><a class="nounderline abstract_t">Psyrri A, Fayette J, Harrington K, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol 2023; 34:262.</a></li><li><a class="nounderline abstract_t">Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 2019; 121:123.</a></li><li><a class="nounderline abstract_t">Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578.</a></li><li><a class="nounderline abstract_t">Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568.</a></li><li><a class="nounderline abstract_t">Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2012; 10:1391.</a></li><li><a class="nounderline abstract_t">Ho AL, Brana I, Haddad R, et al. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol 2021; 39:1856.</a></li><li><a class="nounderline abstract_t">Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021; 22:883.</a></li><li><a class="nounderline abstract_t">Chung CH, Li J, Steuer CE, et al. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2022; 28:2329.</a></li><li><a class="nounderline abstract_t">Bauman JE, Saba NF, Roe D, et al. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol 2023; 41:3851.</a></li><li><a class="nounderline abstract_t">Patil VM, Noronha V, Joshi A, et al. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. J Clin Oncol 2019; 37:3032.</a></li><li><a class="nounderline abstract_t">Patil VM, Noronha V, Menon N, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol 2023; 41:222.</a></li><li><a class="nounderline abstract_t">Michel L, Ley J, Wildes TM, et al. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2016; 58:41.</a></li><li><a class="nounderline abstract_t">Adkins D, Ley J, Neupane P, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol 2019; 20:1295.</a></li><li><a class="nounderline abstract_t">Adkins D, Lin JC, Sacco AG, Le JC. Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS). J Clin Oncol 2019; 37:15S.</a></li><li><a class="nounderline abstract_t">Oppelt P, Ley JC, Worden F, et al. Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. Oral Oncol 2021; 114:105164.</a></li><li><a class="nounderline abstract_t">Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77.</a></li><li><a class="nounderline abstract_t">Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp; Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015; 16:583.</a></li><li><a class="nounderline abstract_t">Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013; 31:1405.</a></li><li><a class="nounderline abstract_t">Kochanny SE, Worden FP, Adkins DR, et al. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer 2020; 126:2146.</a></li><li><a class="nounderline abstract_t">Guo Y, Ahn MJ, Chan A, et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp; Neck 3): an open-label, randomised phase III trial. Ann Oncol 2019; 30:1831.</a></li></ol></div><div id="topicVersionRevision">Topic 3364 Version 96.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1634913" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732427" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2414023" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709437" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452834" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722034" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181673" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181673" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27718784" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509740" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955135" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541678" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Carboplatin versus cisplatin in solid tumors: an analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458260" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6190545" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178667" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7522527" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4040550" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3568273" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High-dose cisplatin in advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912521" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3300967" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751897" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616547" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : [Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8002371" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : [Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3531424" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784101" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Platinum-based chemotherapy plus cetuximab in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15341981" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918125" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781605" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Docetaxel in head and neck cancer: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610709" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24496920" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809151" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743152" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&amp;N Ca) (abstract #5331)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322304" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495923" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289630" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16149285" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gemcitabine in the treatment of advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918127" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20485287" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531245" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343546" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20922785" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22434360" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7536031" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538161" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476477" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Expert Consensus Document on Pulmonary Metastasectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699911" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10493626" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pulmonary metastasectomy for head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357009" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Surgical resection for oral tongue cancer pulmonary metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374506" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Stereotactic body radiotherapy for oligometastatic lung tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822275" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31679945" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35333599" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36219809" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35679031" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33684370" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33684370" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577117" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15908667" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10076732" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896109" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997812" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115384" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585868" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9470832" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745288" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530488" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166832" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865152" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16779801" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590379" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546862" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10776971" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16739325" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001121" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552033" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283932" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746666" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31618129" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36473143" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37022706" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33751752" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247226" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27646946" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28328302" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28651929" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29866947" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246283" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31239321" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31239321" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576970" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32294530" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36535565" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31574417" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009949" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009950" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138167" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33750196" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33989559" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344035" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36977289" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31539316" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36265101" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311401" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31351869" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33465681" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14701768" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892145" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head&amp;Neck 1): an open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460714" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073648" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501887" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head&amp;Neck 3): an open-label, randomised phase III trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
